OBT and Boehringer Ingelheim (BI) have been collaborating since 2013. Our initial collaboration yielded two partnered clinical products and based on this success we entered into a second collaboration in Q4 2020. Our 2020 collaboration has already yielded a program for which BI has exercised an exclusive option. In 2023, we extended our second collaboration for an additional two years, adding further programs into the existing collaboration. 

OBT has licensed a novel, pre-clinical, first-in-class immuno-oncology (IO) antibody to Genmab. This deal represents the first major agreement for one of our IO programs to a world leader in antibody-based oncology medicines. The target related to the antibody was discovered using OBT’s proprietary OGAP® drug discovery platform. 
 
Under the agreement, Genmab is responsible for the future development and commercialization of any products incorporating this antibody.

OBT is collaborating with ImmunoGen, a leader in the expanding field of ADCs for the treatment of cancer, to develop novel antibody drug conjugates to address cancers of high unmet need. The partnership is leveraging OBT's proprietary OGAP® discovery platform to identify new targets to be coupled with ImmunoGen's ADC linker-payload technology. Both companies have the opportunity to select multiple programs to develop independently.  

ImmunoGen's ADC platform and DM4 payload is utilized in OBT's lead program OBT076.

OBT is collaborating with Agenus, an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response to cancer and infections. OBT will sponsor a clinical trial evaluating the combination of OBT076 with Agenus' anti-PD-1 checkpoint inhibitor Balstilimab, which is currently in clinical development in several solid tumor indications.  

GORTEC (Groupe d'Oncologie Radiothérapie Tête Et Cou)

OBT is collaborating with GORTEC, to conduct a Phase 1b trial investigating OBT's lead asset, OBT076, in patents with adenoid cystic carcinoma (ACC). GORTEC is a well-established, internationally renowned, European oncology and radiotherapy consortium specialising in clinical and laboratory research specifically for the benefit of head and neck cancer patients. The trial is investigating OBT076 as a monotherapy and in combination with Agenus' proprietary checkpoint inhibitor (CPI), balstilimab. 

Through this collaboration, OBT will validate up to five novel oncology drug targets, previous identified using OBT's OGAP® discovery platform, and generate antibodies against them. Kite, a Gilead Company, will have the exclusive right to develop and commercialize therapies based on these targets and antibodies. 

​